Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Precigen reported revenue of $10M in the fiscal year ended Dec 2025, up 146.7% from the year before. Operating income was −$111M, an operating margin of −1141.1%, and net income was −$251M. Operating cash flow of −$88M less capital expenditure of $2M left free cash flow of −$90M. Net debt was $63M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.3 | 26.9 | 6.2 | 3.9 | 9.7 |
| Research & development | – | – | 48.6 | 53.1 | 41.3 |
| Selling, general & admin | – | – | 40.4 | 41.3 | 70.1 |
| Operating incomederived: pre-tax income + interest | −111 | −80.0 | −99.8 | −135 | −111 |
| Interest expense | – | – | 0.5 | 0.0 | 3.9 |
| Pre-tax income | −111 | −80.0 | −96.4 | −128 | −251 |
| Income tax | −0.2 | −0.2 | −0.5 | −1.8 | 0.0 |
| Net income | −92.2 | 28.3 | −95.9 | −126 | −251 |
| Diluted EPS | −0.47 | 0.14 | −0.39 | −0.47 | −1.37 |
| Diluted shares | 198 | 200 | 245 | 268 | 313 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 36.4 | 4.9 | 7.6 | 29.5 | 30.2 |
| Receivables | 1.3 | 1.0 | 0.9 | 0.9 | 3.9 |
| Current assets | 157 | 118 | 68.8 | 102 | 115 |
| Net PP&E | 8.6 | 7.3 | 7.1 | 13.8 | 13.8 |
| Goodwill | 37.6 | 36.9 | 26.6 | 19.1 | 15.2 |
| Total assets | 360 | 216 | 151 | 145 | 156 |
| Payables | 3.1 | 4.1 | 1.7 | 3.5 | 12.0 |
| Deferred revenue | 1.5 | 0.0 | 0.5 | 0.6 | 0.5 |
| Current liabilities | 34.6 | 78.6 | 23.0 | 21.5 | 37.3 |
| Short-term debt | 0.1 | 43.2 | 0.0 | – | – |
| Long-term debt | 180 | 0.0 | – | 0.0 | 93.2 |
| Total liabilities | 253 | 89.7 | 32.5 | 78.5 | 135 |
| Shareholders' equity | 107 | 126 | 118 | 38.5 | 20.9 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −55.8 | −65.0 | −66.9 | −68.2 | −87.8 |
| Capital expenditure | 7.2 | 4.9 | 1.5 | 8.6 | 2.0 |
| Free cash flow | −63.0 | −70.0 | −68.5 | −76.8 | −89.8 |
| Depreciation & amortisation | 13.8 | 10.8 | 6.7 | 4.5 | 3.2 |
| Stock-based compensation | 13.9 | 10.2 | 9.9 | 9.5 | 10.9 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 88.6% | −76.9% | −36.9% | 146.7% |
| EPS growth (YoY) | – | – | −378.6% | – | – |
| Operating margin | −777.8% | −297.2% | −1602.5% | −3440.2% | −1141.1% |
| Net margin | −646.0% | 105.2% | −1540.6% | −3216.2% | −2588.2% |
| Return on equityBlank when equity is negative | −85.9% | 22.4% | −80.9% | −327.8% | −1198.6% |
| ROCEEBIT ÷ (assets − current liabilities) | −34.1% | −58.2% | −77.9% | −109.1% | −93.5% |
| Free cash flow margin | −441.7% | −260.0% | −1099.9% | −1955.6% | −927.6% |
| Cash conversion (CFO ÷ net income) | 0.61x | −2.30x | 0.70x | 0.54x | 0.35x |
| Receivable days | 34 | 13 | 53 | 86 | 148 |
| Interest cover | – | – | −213x | −22505x | −28.6x |
| Debt ÷ equity | 1.68x | 0.34x | – | 0.00x | 4.46x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | 144 | 38.4 | – | −29.5 | 62.9 |
| Current ratio | 4.52x | 1.50x | 2.99x | 4.76x | 3.09x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.